PCN16 COST OF MANAGING SIDE EFFECTS OF FIRST-LINE BEVACIZUMAB (BEV) + LOWER-DOSE INTERFERON-ALPHA2A IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN GERMANY, FRANCE, AND UNITED KINGDOM

Saved in:
Bibliographic Details
Published inValue in health Vol. 12; no. 3; pp. A38 - A39
Main Authors Mickisch, GH, Escudier, B, Gore, M, Walzer, S, Nuijten, MJ
Format Journal Article
LanguageEnglish
Published Elsevier Inc 2009
Subjects
Internal Medicine
Online AccessGet full text

Cover

More Information
ISSN:1098-3015
1524-4733
DOI:10.1016/S1098-3015(10)73253-8